Selecting and Sequencing of HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.
A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Reshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.
Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.